Biography:Nicholas Lydon
Nicholas Lydon | |
|---|---|
 | |
| Born | 27 February 1957 [citation needed] |
| Alma mater |
|
| Known for |
|
| Awards |
|
| Scientific career | |
| Institutions |
|
| Thesis | Studies on the hormone-sensitive adenylate cyclase from bovine corpus luteum (1982) |
| Website | royalsociety |
Nicholas B. Lydon FRS (born 27 February 1957) is a British scientist and entrepreneur.[1] In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition.[2][3][4][5] [6][7]
Education
Lydon was educated at Strathallan School near Perth, Scotland.[8] He earned a Bachelor of Science degree in biochemistry from the University of Leeds, England in 1978 and received his PhD in biochemistry from the University of Dundee, Scotland in 1982.[8][9]
Career
In 1982, Lydon accepted a position with Schering-Plough based in France as Chargé de Récherche.[3] Three years later, he moved to Switzerland to work with Ciba-Geigy Pharmaceuticals, with whom he developed Gleevec.[8] In 1997, he established Kinetex Pharmaceuticals in Boston which was acquired by Amgen in 2000, with whom he worked until 2002.[8] Thereafter, he established several companies that continue to develop drugs to treat various conditions.[8]
Honours and awards
- Warren Alpert Foundation Prize, 2000.[3]
- Twenty First Annual AACR-Bruce F. Cain Memorial Award, 2002.[3]
- Charles F. Kettering Prize, General Motors Cancer Research Foundation, 2002.[3]
- The Lasker-DeBakey Clinical Medical Research Award, with Brian Druker and Charles Sawyers, 2009.[3]
- The Japan Prize, with Brian Druker and Janet Rowley, 2012.[3]
- Fellow of the Royal Society, 2013.[10]
- Royal Society GlaxoSmithKline Prize and Lecture, 2014[11]
Lydon's nomination for the Royal Society reads:
| “ | Nick Lydon played a decisive role in the development of Gleevec (Imatinib), a drug that has saved the lives of thousands of patients with chronic myelogenous leukaemia (CML) and gastrointestinal stromal tumours (GIST). Gleevec revolutionised the field of cancer drug discovery by changing rapidly fatal diseases into easily treatable conditions, and showed that, by targeting an oncogene that is the molecular cause of a specific cancer, the defective cancer cells can be killed without any major side effects on normal cells. The remarkable efficacy of Gleevec profoundly changed the perception of protein kinases as therapeutic targets. From being considered to be virtually "undruggable" in 1994, they have become the pharmaceutical industry's most popular class of drug target today, accounting for over 50% of cancer drug discovery R&D. The international prizes that Nick Lydon has received include, most recently, the Lasker-DeBakey Clinical Medical Research Award from The Lasker Foundation.[10] | ” |
References
- ↑ "Nicholas Lydon". 2010. http://www.scienceheroes.com/index.php?option=com_content&view=article&id=379&Itemid=312.
- ↑ "Lasker – DeBakey Clinical Medical Research Award: Award Description". Lasker Foundation. http://www.laskerfoundation.org/awards/2009_c_description.htm.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 "Laureates of the Japan Prize". The Japan Prize Foundation. 2012. http://www.japanprize.jp/en/prize_prof_2012_b_lydon.html.
- ↑ Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H. et al. (2001). "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia". New England Journal of Medicine 344 (14): 1031–1037. doi:10.1056/NEJM200104053441401. PMID 11287972.
- ↑ List of publications from Microsoft Academic
- ↑ Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. (1996). "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells". Nature Medicine 2 (5): 561–566. doi:10.1038/nm0596-561. PMID 8616716.
- ↑ Buchdunger, E.; Cioffi, C. L.; Law, N.; Stover, D.; Ohno-Jones, S.; Druker, B. J.; Lydon, N. B. (2000). "Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors". The Journal of Pharmacology and Experimental Therapeutics 295 (1): 139–145. PMID 10991971.
- ↑ 8.0 8.1 8.2 8.3 8.4 "Dr Nicholas Lydon". University of Dundee. 2011. http://www.ppu.mrc.ac.uk/resources/Nick_Lydon_Laureation.doc.
- ↑ Lydon, Nicholas B. (1982). Studies on the hormone-sensitive adenylate cyclase from bovine corpus luteum (PhD thesis). University of Dundee. Cite has empty unknown parameter:
|1=(help)(Subscription content?) - ↑ 10.0 10.1 "Dr Nicholas Lydon". Royal Society. 2013. http://royalsociety.org/people/nicholas-lydon/.
- ↑ "GlaxoSmithKline prize". Royal Society. http://royalsociety.org/awards/glaxosmithkline-prize-lecture/.
 |  |
